Fig. 8

Validation of the independent predictive ability of WT1 in thyroid cancer patients. A Forest plot showing the prognostic performance of WT1 and other clinical features in THCA cohort patients in the TCGA database. B The nomogram showing the predicted overall survival rate of thyroid cancer patients at 1 year, 3 years and 5 years on the basis of independent prognostic factors including TNM stage and WT1 expression level. C–E Calibration curves revealing superior consistency of the predictive nomogram model at 1 year, 3 years and 5 years. F The relationship between WT1 expression, BRAF mutated status and TNM stage in thyroid cancer patients. G, H K-M survival analysis implied the prognostic value of WT1 in thyroid cancer patients carrying BRAF mutation or BRAF wild-type. I Schematic of mechanism of BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma